Entries |
Document | Title | Date |
20090060997 | PROCESS FOR PRODUCING A PHARMACEUTICAL PREPARATION FOR THERAPEUTIC TREATMENT OF ENDOMETRIOSIS CONTAINING A COMBINATION OF A GESTAGEN AND (6S)-5-METHYLTETRAHYDROFOLATE - A combination of an anti-androgenic gestagen at a daily dose of from an ovulation-inhibiting dose up to at most twice the ovulation-inhibiting dose and from 0.1 to 10 mg of (6S)-5-methyltetrahydrofolate are used to produce a pharmaceutical preparation for therapeutically treating endometriosis while simultaneously reducing therapy side effects including the negative effect on bone density and/or bone metabolism, reducing the risk of osteoporosis and, in the event of pregnancy, reducing the risk of congenital malformations, such as medullary tube defects, cleft lip, cleft jaw, or cleft palate, and the risk of pregnancy complications, such as detachment of the placenta and premature birth. The preparation is suitable for long-term administration, which continues daily for at least 169 days to at least two years. | 03-05-2009 |
20090068268 | MELT GRANULATION OF A COMPOSITION CONTAINING A CALCIUM-CONTAINING COMPOUND - A novel method for the preparation of a tablet comprising a calcium-containing compound, the method involves a melt granulation process by which a sugar alcohol is melted and embeds the calcium-containing compound so that a sufficient taste masking of the chalkiness is substantially achieved and an unpleasant mouth feel of the calcium-containing compound is substantially avoided, while at the same time obtaining a low tablet volume. The method of the invention is especially suitable for the manufacturing of tablets having a high load of a calcium-containing compound. | 03-12-2009 |
20090123542 | PRIMARY COMPOSITION COMPRISING A LIPOPHILIC BIOACTIVE COMPOUND - The invention relates to a primary composition in which at least one lipophilic bioactive compound is mixed with a whey protein, present in an amount effective to increase the bioavailability of the lipophilic bioactive compound. The invention also relates to an oral composition that contains the primary composition in a foodstuff, in a food supplement, or in a pharmaceutical preparation, and to a cosmetic preparation that contains the primary composition. Methods for increasing the bioavailability of the lipophilic bioactive compound and providing increased photostability and oxidation resistance are also provided. | 05-14-2009 |
20090130210 | PHARMACEUTICAL COMPOSITIONS OF SIROLIMUS - A pharmaceutical composition of sirolimus comprising an inert core and a sugar overcoat, wherein said sugar overcoat comprises sirolimus, a poloxamer other than poloxamer 188, microcrystalline cellulose and binder has been developed. | 05-21-2009 |
20090175940 | Solubilized ibuprofen - A process for producing a solubilized ibuprofen, preferably in the form of a granulate, the process comprising the steps of: providing a mixture comprising solid ibuprofen and a first base selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium glycinate, potassium glycinate and tribasic sodium and potassium phosphates and mixtures thereof, and reacting the ibuprofen and the first base in essentially dry state. The obtainable granulate and the pharmaceutical compositions and dosage forms that may be produced therefrom are distinguished by their high solubility and rapid disintegration and dissolution in aqueous media, by their good flow properties and compressibility, by rapidly achieving onset of analgesic effect. | 07-09-2009 |
20090196925 | NATURAL PRODUCT COATING FOR TABLETS - An all-natural tablet coating composition comprised entirely of Certified Organic ingredients and organic compliant ingredients which can be applied to a compressed tablet core using conventional film coating techniques is provided. The coating is useful for preparing organic dietary supplements in a coated tablet form that exhibits good physical and chemical stability, good aesthetics, and which is free of synthetic materials. | 08-06-2009 |
20090208576 | Orally Disintegrating Tablets - The present invention describes a directly compressible composite prepared by co-processing a water-soluble excipient and calcium silicate. The present invention further describes the incorporation of the co-processed composite into a tablet formulation. The orally disintegrating tablets are of optimal mechanical strength and disintegrate within 60 seconds in the oral cavity. | 08-20-2009 |
20100047349 | Stabilized solid preparation - A stabilized solid preparation having stabilized drug content and stabilized appearance, comprising a main ingredient layer and a coating layer formed on the main ingredient layer, wherein the main ingredient layer comprises a granule or a fine particle comprising a substance capable of being unstabilized when losing water of crystallization and a water-soluble polymer and the coating layer comprises a water-soluble polymer and a sugar. | 02-25-2010 |
20100112056 | IMMEDIATE RELEASE DOSAGE FORMS OF SODIUM OXYBATE - The present invention provides a pharmaceutical composition, presented as a solid unit dosage form adapted for oral administration of sodium oxybate. The preferred unit dosage form is a tablet comprising a relatively high weight-percentage of sodium oxybate, in combination with a relatively small weight-percentage of total excipients. This permits the tablets to contain/deliver a pharmaceutically effective amount, e.g., about 0.5-1.5 g of sodium oxybate in each tablet with a delivery profile similar to that of the liquid form. The tablets are bioequivalent to the liquid form. | 05-06-2010 |
20100151024 | THERAPEUTIC AGENT FOR ULCERATIVE COLITIS - A method for treating a patient having ulcerative colitis, by administering a drug which containing an effective amount of tetracyclines is provided. The drug may also contain penicillins and/or metronidazoles. | 06-17-2010 |
20100183718 | COMPOSITIONS AND TREATMENT OF HEART DEFICIENCY IN NON-HUMAN ANIMALS - The invention relates to novel compositions including an aldosterone antagonist and administered according to a predetermined dosage for treating heart deficiency in non-human mammals. | 07-22-2010 |
20100297230 | COMPOSITIONS AND METHODS FOR PROSTATE AND MENSTRUAL/MENOPAUSAL RELATED HEALTH - The disclosure provides compositions and methods and maintaining prostate health and relieving menstrual and menopausal related symptoms. The compositions comprise at least two of an icariin component, a quercetin component, a Maca component, a cocoa polyphenols component, and/or a rosmarinic acid component. | 11-25-2010 |
20100323013 | HYDROLYSATES MADE OF PLANT EXTRACTS AND ANTIBACTERIAL AGENT CONTAINING THE SAME - The present invention relates to an antibacterial agent and a hydrolysate made of at least one extract that has been produced by extraction using ethanol/water from dried plant material of: a) at least one of the plants selected from the group consisting of: | 12-23-2010 |
20110014286 | MIXTURE FOR PRODUCING RAPIDLY DISINTEGRATING TABLETS - An isomalt-containing mixture including a) 60-97% by weight of agglomerated isomalt, b) 1-25% by weight of crosslinked polyvinylpyrrolidone, c) 0.1-15% by weight of lubricant, d) 1-15% by weight of water-insoluble, film-forming polymers, e) 0-15% by weight of water-soluble polymers and f) 0-15% by weight of pharmaceutical auxiliaries, where the sum of components a) to f) is 100% by weight. Also processes for the preparation of the isomalt-containing mixture and tablets comprising the mixture. | 01-20-2011 |
20110097401 | METHODS FOR TREATING GASTROINTESTINAL DISORDERS - Provided herein are compositions and formulations suitable for the treatment of gastrointestinal disorders. Also provided are methods for treating, preventing, or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus. | 04-28-2011 |
20110244041 | PLANT EXTRACT HYDROLYSATES AND ANTIBACTERIAL PRODUCT CONTAINING THE SAME - The invention relates to a hydrolyzate from at least one extract of at least one plant material selected from the group consisting of at least one genus: | 10-06-2011 |
20110305759 | COMPOSITION COMPRISING CALCIUM CARBONATE AS A WHITE PIGMENT - A white colouring composition comprising calcium carbonate as a white pigment. It may be used in the manufacture of food and pharmaceutical products. | 12-15-2011 |
20120058185 | STABLE PHARMACEUTICAL COMPOSITIONS OF OLANZAPINE AND PROCESS FOR THEIR PREPARATION - The present invention provides a stable pharmaceutical composition of Olanzapine or its pharmaceutically acceptable salt comprising coated tablet formulations of Olanzapine or its pharmaceutically acceptable salt, wherein the coating consists essentially of pectin or copovidone, and a process of making the same. | 03-08-2012 |
20120070497 | USE OF BOSWELLIC ACIDS FOR THE PROPHYLAXIS AND/OR TREATMENT OF DAMAGE TO AND/OR INFLAMMATION OF THE ISLETS OF LANGERHANS - Disclosed are methods and compositions related to the use of boswellic acids (such as acetyl-11-keto-β-boswellic acid, 11-keto-β-boswellic acid, β-boswellic acid, acetyl-β-boswellic acid, 9,11-dehydro-β-boswellic acid, acetyl-9,11-dehydro-β-boswellic acid, α-boswellic acid, acetyl-α-boswellic acid, 11-dehydro-α-boswellic acid, acetyl-9,11-dehydro-α-boswellic acid, lupeolic acid, acetyl lupeolic acid, 12-ursene-2-diketone, incensole, incensole acetate, a derivative, in particular an ester thereof, a pharmaceutically acceptable salt thereof, a combination thereof, or a preparation containing one or more of these compounds) for the human medical or veterinary prophylaxis and/or treatment of: a) damage to and/or inflammation of the islets of Langerhans and/or b) damage to the B-cells of the islets of Langerhans. | 03-22-2012 |
20120076857 | FORMS OF RIFAXIMIN AND USES THEREOF - The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them. | 03-29-2012 |
20120082723 | Easily administrable solid preparation - It is an object to provide a coating composition, which is used for an orally-administered preparation, the administering property of which has been improved, and/or an easily administrable preparation that does not affect dissolution property. The aforementioned object can be achieved using a coating composition comprising a first thickener selected from the group consisting of a carboxyvinyl polymer and sodium alginate, a polyvalent metal compound, and at least one type of a second thickener selected from the group consisting of xanthan gum, guar gum and sodium alginate, with the proviso that when the first thickener is sodium alginate the second thickener is not sodium alginate, or using a coating composition comprising, as thickeners, hydroxypropylmethylcellulose and sugar or sugar alcohol having a solubility at 20° C. of 30 or more. | 04-05-2012 |
20120135078 | ANGINA TREATMENT - A xanthine oxidase inhibitor for use in the treatment of angina is described. The angina may be stable angina pectoris and the treatment may be to eliminate, reduce or alleviate one or more symptoms of angina pectoris (such as chest pain), or may be prophylactic. The xanthine oxidase inhibitor may be used in combination with one or more additional therapeutic agents, such as anti-anginal agents. Pharmaceutical compositions, medicaments and kits for the treatment of angina are also described. | 05-31-2012 |
20120177738 | GREEN TEA EXTRACTS OF IMPROVED BIOAVAILABILITY - The present invention relates to a green tea formulation stabilized by natural antioxidants such as OPC together with vitamin C or vitamin C analogs. The invention also relates to the use of a mixture of OPC and ascorbic acid to increase bioavailability of green tea catechins. It also relates to a food, pharmaceutical or cosmetic composition that contains the stabilized green tea formulation. | 07-12-2012 |
20120183614 | POLYPHENOL COMPOUND ABSORPTION PROMOTER AND UTILIZATION OF SAME - Provided are a polyphenol compound absorption promoter which is widely applicable to foods and drinks over a wide range, and a method for producing a food, drink or food material containing a polyphenol compound. The polyphenol compound absorption promoter comprises, as the active ingredient, at least one member selected from the group consisting of serine, aspartic acid, malic acid, capric acid, lauric acid, grapefruit juice and | 07-19-2012 |
20120207833 | FORMS OF RIFAXIMIN AND USES THEREOF - Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them. | 08-16-2012 |
20120282339 | ELECTROLYTE PURGATIVE - The invention relates to compositions for use in purgatives, to purgatives comprising such compositions, and to methods for inducing purgation of the colon. The composition may comprise at least one water-soluble sodium salt; at least one water-soluble minimally degradable sugar in an amount, by weight, of from about 1 to about 3 times the weight of sodium ions in said composition; at least one water-soluble potassium salt in an amount, by weight, of from about 0.05 to about 1 time the weight of said sodium salt in said composition; and at least one water-soluble magnesium salt, wherein the weight of magnesium ions in said composition is from 0.1 to about 10 times the weight of sodium ions in said composition. | 11-08-2012 |
20120308656 | SUGAR-COATED PREPARATION AND PRODUCTION METHOD FOR THE SAME - A method is provided for producing a sugar-coated preparation including a solid composition containing a pharmacologically active ingredient and a sugar coating layer. The method comprises a step of forming the sugar coating layer with a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. The sugar-coated preparation includes a solid composition containing a pharmacologically active ingredient and a sugar coating layer, wherein the sugar coating layer is made of a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. | 12-06-2012 |
20120315332 | PHARMACEUTICAL COMPOSITION INCLUDING SUNFLOWER EXTRACT, PREPARATIVE METHOD AND USE THEREOF - A pharmaceutical composition containing sunflower extract comprises the extract of total flavonoids from leaves, heads or stems of sunflower ( | 12-13-2012 |
20130034607 | TABLET - The present invention provides a novel tablet with improved tablet appearance and improved swallowability. The tablet contains a pharmaceutically acceptable anion exchange resin represented by colestimide as an active ingredient, and has a visibility-resolved tablet edge. | 02-07-2013 |
20130089610 | R(+)-N-METHYL-PROPARGYL-AMINOINDAN - The subject invention provides R(+)-N-methyl-propargyl-aminoindan or a pharmaceutically acceptable salt thereof and a composition containing R(+)-N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-methyl-propargyl-aminoindan or a salt thereof. | 04-11-2013 |
20130089611 | RASAGILINE CITRAMIDE - The subject invention provides rasagiline citramide and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of rasagiline citramide or a salt thereof. | 04-11-2013 |
20130089612 | R(+)-N-FORMYL-PROPARGYL-AMINOINDAN - The subject invention provides R(+)-N-formyl-propargyl-aminoindan and a composition containing N-propargyl-1(R)-aminoindan or a pharmaceutically acceptable salt thereof, and a compound of R(+)-N-formyl-propargyl-aminoindan. | 04-11-2013 |
20130089613 | Compounds Having Activating Effect on Subtypes of Peroxisome Proliferator-Activated Receptors and its Preparation Method and Uses - Phenyl propanoic acid compounds having activating effect on peroxisome proliferator-activated receptors (PPARα,δ,γ) and a preparation method and uses thereof are provided in the present invention. The compounds can be used for treating or preventing diseases associated with peroxisome proliferator-activated receptors (PPARα,δ,γ). | 04-11-2013 |
20130202703 | METHOD FOR PRODUCING GARDENIA BLUE PIGMENT - Provided is a method for producing a gardenia blue pigment resistant to discoloration which may occur in colored sugar-coated food or pharmaceutical products. The method for producing such a gardenia blue pigment comprises performing membrane separation using a membrane (for example, an ultrafiltration membrane) with a molecular weight cut-off of 3000 Da or larger for removal of low-molecular compounds from a solution resulting from β-glucosidase treatment of an iridoid glycoside (for example, geniposide etc.) in the presence of a protein hydrolysate (for example, a casein protein hydrolysate), the iridoid glycoside being obtainable by extraction from fruits of | 08-08-2013 |
20130230592 | NOVEL OMEGA-3 AND OMEGA-6 FATTY ACID COMPOSITIONS AND USES THEREOF - A composition for use in preventing and/or treating and/or reducing organic, including symptomatic, mental disorders, comprising:
| 09-05-2013 |
20130236546 | THYME/PRIMROSE OR IVY FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD) - The invention relates to an extract made of thyme ( | 09-12-2013 |
20130295179 | NOVEL OMEGA-3 AND OMEGA-6 FATTY ACID COMPOSITIONS AND USES THEREOF - The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising:
| 11-07-2013 |
20140099368 | DOSAGE FORMS OF ACTIVE INGREDIENTS CONTAINING HYDROXYSTILBENE FOR TREATING MENOPAUSAL COMPLAINTS - The invention provides novel hydroxystilbene-containing dosage forms, processes for producing these dosage forms and the use thereof for the treatment of menopausal symptoms in women, juvenile oligomenorrhea and dysmenorrhea, primary and secondary amenorrhea or endometritis. | 04-10-2014 |
20140147501 | METHOD FOR THE EMBEDDING AND ENCAPSULATION OF COMPONENTS - Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biologically, or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The additional component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass. The plasticizer content is substantially reduced and the temperature of the plasticized mass are substantially reduced prior to admixing the plasticized mass with the encapsulant to avoid substantial destruction of the encapsulant and to obtain a formable, extrudable mixture. The mixture is extruded through a die without substantial or essentially no expansion and cut into discrete, relatively dense particles. Release properties may also be controlled by precoating the encapsulant and/or coating the extrudate particles with a film-forming component. | 05-29-2014 |
20140147502 | HYDROLYSATES MADE OF PLANT EXTRACTS AND ANTIBACTERIAL AGENT CONTAINING THE SAME - The present invention relates to an antibacterial agent and a hydrolysate made of at least one extract that has been produced by extraction using ethanol/water from dried plant material of: a) at least one of the plants selected from the group consisting of: | 05-29-2014 |
20140255485 | COLLAGEN HYDROLYSATE AND USE THEREOF - The present invention relates to collagen hydrolysate and the use thereof for treating and/or preventing cellulite. | 09-11-2014 |
20140322324 | Composition For The Treatment Of Bacterial Infections - Composition for use in treating bacterial infections, comprising a concentrate or an extract of | 10-30-2014 |
20140335180 | PRODUCTS FOR ORAL ADMINISTRATION COMPRISING EXTRACTS OF PUNICA GRANATUM (POMEGRANATE), INTENDED FOR A PET, AND APPLICATIONS OF SAME - The invention relates to a product for oral administration intended for a pet, comprising extracts of | 11-13-2014 |
20150118307 | FORMS OF RIFAXIMIN AND USES THEREOF - Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them. | 04-30-2015 |
20150320793 | Compositions and Solutions for Colon Cleansing - The invention relates to polysiloxanes contained as defoaming agents, amongst other things, in medicinal compositions such colon cleansing solutions and antiflatulants. The aim of the invention is to further improve the defoaming effect of polysiloxanes and also the compatibility of the agents. According to the invention, the use of calcium sulphate increases the defoaming effect of dimeticon or simeticon as polysiloxane defoaming agents. The invention also relates to PEG-containing colon cleaning solutions based thereon. | 11-12-2015 |
20160031897 | FORMS OF RIFAXIMIN AND USES THEREOF - Embodiments relate to Rifaximin polymorphic, salt, and hydrate forms, methods of producing polymorphic forms and to their use in medicinal preparations and to therapeutic methods using them. | 02-04-2016 |
20160051478 | FILM-FORMING COMPOSTIONS FOR THE FILM-COATING OF SOLID FORMS - A film-forming composition including a fluidized hydroxypropyl starch and sorbitol, a film-coating method using the composition, and film-coated solid forms including a fluidized hydroxypropyl starch and sorbitol in the coating are described. | 02-25-2016 |
20160136091 | Orally Disintegrating Tablet - Disclosed is an orally disintegrating tablet including: (a) an active ingredient; (b) a starch with an amylose content of 20% by mass to 30% by mass and a degree of gelatinization of less than 10%; and (c) at least one inorganic excipient selected from the group consisting of magnesium silicate, calcium silicate, and synthetic hydrotalcite. The orally disintegrating tablet is a single-layer tablet or a dry-coated tablet having an inner core and an outer layer. The orally disintegrating tablet as a single-layer tablet or the outer layer of the orally disintegrating tablet as a dry-coated tablet has a crystalline cellulose content of 0% by mass to 5% by mass. | 05-19-2016 |